Variation in prescribing of lipid‐lowering medication in primary care is associated with incidence of cardiovascular disease and all‐cause mortality in people with screen‐detected diabetes: findings from the ADDITION‐Denmark trial
Open Access
- 29 September 2014
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 31 (12) , 1577-1585
Abstract
Aims: To examine variation between general practices in the prescription of lipid‐lowering treatment to people with screen‐detected Type 2 diabetes, and associations with practice and participant characteristics and risk of cardiovascular events and all‐cause mortality.Methods: Observational cohort analysis of data from 1533 people with screen‐detected Type 2 diabetes aged 40–69 years from the ADDITION‐Denmark study. One hundred and seventy‐four general practices were cluster randomized to receive: (1) routine diabetes care according to national guidelines (623 individuals), or (2) intensive multifactorial target‐driven management (910 individuals). Multivariable logistic regression was used to quantify the association between the proportion of individuals in each practice who redeemed prescriptions for lipid‐lowering medication in the two years following diabetes diagnosis and a composite cardiovascular disease (CVD) outcome, adjusting for age, sex, prevalent chronic disease, baseline CVD risk factors, smoking and lipid‐lowering medication, and follow‐up time.Results: The proportion of individuals treated with lipid‐lowering medication varied widely between practices (0–100%). There were 118 CVD events over 9431 person‐years of follow‐up. For the whole trial cohort, the risk of CVD was significantly higher in practices in the lowest compared with the highest quartile for prescribing lipid‐lowering medication [adjusted odds ratio (OR) 3.4, 95% confidence interval (CI) 1.6–7.3]. Similar trends were found for all‐cause mortality.Conclusions: More frequent prescription of lipid‐lowering treatment was associated with a lower incidence of CVD and all‐cause mortality. Improved understanding of factors underlying practice variation in prescribing may enable more frequent use of lipid‐lowering treatment. The results highlight the benefits of intensive treatment of people with screen‐detected diabetes (Clinical Trials Registry No; NCT 00237549).Keywords
Funding Information
- ASTRA Denmark
- Danish Council for Strategic Research
- GlaxoSmithKline Pharma Denmark
- National Health Services in Denmark
- Novo Nordisk AS
- Novo Nordisk Foundation
- Novo Nordisk Scandinavia AB
- Novo Nordisk UK
- Pfizer Denmark
- SERVIER Denmark A/S
- The Aarhus University Research Foundation
- the Danish Centre for Evaluation and Health Technology Assessment
- The Danish Medical Research Council
- The Danish Research Foundation for General Practice
- the diabetes fund of the National Board of Health
This publication has 24 references indexed in Scilit:
- Government prioritises health checks for 15 million adults despite pre-election promise to scrap them2013
- Statins for the primary prevention of cardiovascular diseaseCochrane Database of Systematic Reviews, 2013
- All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, DenmarkPrimary Care Diabetes, 2012
- [No evidence for population-based screening for type 2-diabetes].2012
- Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based StudyPLOS ONE, 2012
- Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trialThe Lancet, 2011
- Improved quality of Type 2 diabetes care following electronic feedback of treatment status to general practitioners: a cluster randomized controlled trialDiabetic Medicine, 2011
- Effect of “motivational interviewing” on quality of care measures in screen detected type 2 diabetes patients: A one-year follow-up of an RCT, ADDITION DenmarkScandinavian Journal of Primary Health Care, 2011
- Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish populationPrimary Care Diabetes, 2007
- Socioeconomic gradient in use of statins among Danish patients: population‐based cross‐sectional studyBritish Journal of Clinical Pharmacology, 2005